Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more
Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
7.848M
52 Wk Range
$0.25 - $39.84
Previous Close
$0.33
Open
$0.34
Volume
309,703
Day Range
$0.32 - $0.34
Enterprise Value
3.916M
Cash
3.45M
Avg Qtr Burn
-2.689M
Insider Ownership
61.49%
Institutional Own.
6.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Lymphoma, Cancer | Phase 2 Data readout | |
Oral Plogosertib Details Lymphoma, Solid tumor/s | Phase 1 Data readout |